Justin Chakma - Dec 2, 2024 Form 4 Insider Report for ARS Pharmaceuticals, Inc. (SPRY)

Signature
/s/ Kathleen Scott, Attorney-in-Fact
Stock symbol
SPRY
Transactions as of
Dec 2, 2024
Transactions value $
-$1,133,019
Form type
4
Date filed
12/4/2024, 09:45 PM
Previous filing
Nov 27, 2024
Next filing
Dec 6, 2024

Transactions Table

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SPRY Stock Option (Right to Buy) Options Exercise $0 -45K -93.24% $0.00 3.26K Dec 2, 2024 Common Stock 45K $0.84 Direct F3
transaction SPRY Stock Option (Right to Buy) Options Exercise $0 -3.26K -100% $0.00 0 Dec 3, 2024 Common Stock 3.26K $0.84 Direct F3
transaction SPRY Stock Option (Right to Buy) Options Exercise $0 -41.7K -17.66% $0.00 195K Dec 3, 2024 Common Stock 41.7K $0.84 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The weighted average sale price for the transaction reported was $13.6715, and the range of prices were between $13.324 and $14.035. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F2 The weighted average sale price for the transaction reported was $13.1867, and the range of prices were between $13.00 and $13.38. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F3 Immediately exercisable.